abacavir sulfate and lamivudine
abacavir sulfate and lamivudine · ABACAVIR SULFATE 600 mg/1; LAMIVUDINE 300 mg/1 · Tablet, Film Coated · Glaxo Operations UK Ltd
NDC 63379-0094-00 · 41148 TABLET, FILM COATED in 1 DRUM · DRUG FOR FURTHER PROCESSING · View full market →
Bulk ingredient — not a finished product
This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.
Medicare Part D
This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of abacavir sulfate and lamivudine (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Glaxo Operations UK Ltd | ABACAVIR SULFATE 600 mg/1; LAMIVUDINE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "abacavir sulfate and lamivudine — NDC 63379-0094-00," retrieved September 3, 2026, https://drugdashboards.com/drug/63379009400.
Free to cite with attribution — see how the data is put together.